Emergent BioSolutions Receives $30M BARDA Contract for CYFENDUS Vaccine.

Emergent BioSolutions has received a $30 million contract modification from BARDA to supply CYFENDUS vaccine. Deliveries are expected to begin this year and be completed by March 2026. The vaccine is intended to safeguard civilian populations against the potential threat of anthrax. The contract is part of the company's ongoing engagement with the US government to ensure medical countermeasures are readily available.

GAITHERSBURG, Md., September 02, 2025 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) has received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply CYFENDUS®, their FDA-approved two-dose anthrax vaccine. The deliveries are scheduled between late 2025 and March 2026.

This contract modification follows a previous $50 million contract modification announced in December 2024. CYFENDUS®, approved by the FDA in July 2023, is designed for post-exposure prophylaxis use in individuals aged 18-65 when administered with recommended antibacterial drugs. The vaccine addresses anthrax, which is classified as a Tier 1 biological threat due to its potential use in bioterrorism.

The $30 million contract modification from BARDA represents a meaningful revenue catalyst for Emergent BioSolutions, coming just months after their previous $50 million contract modification announced in December 2024. This sequential procurement demonstrates sustained government confidence in Emergent's CYFENDUS® vaccine following its FDA approval in July 2023.

The timing of deliveries is particularly favorable for near-term financials, with shipments beginning this calendar year and completing by March 2026. This provides Emergent with a predictable revenue stream over the next several quarters, which is especially valuable for biodefense contractors who often face lumpy procurement cycles.

Strategically, this contract reinforces Emergent's position in the medical countermeasures market, specifically for protection against anthrax, which remains classified as a Tier 1 biological threat. The U.S.-based supply chain highlighted in the release carries dual significance: it aligns with national security priorities regarding domestic production capabilities for critical medical countermeasures and shields the company from international supply chain disruptions.

This contract also suggests the government's commitment to maintaining readiness against non-pandemic biological threats, even as much public attention has shifted elsewhere. The continued investment in anthrax countermeasures indicates BARDA is maintaining a diversified approach to biodefense preparedness, which benefits specialized suppliers like Emergent.

For investors, this procurement represents not just immediate revenue but validation of Emergent's continued relevance in the biodefense sector, where government relationships and contracting track record are crucial competitive advantages that create barriers to entry for potential competitors.

References:
[1] https://www.stocktitan.net/news/EBS/emergent-bio-solutions-awarded-30-million-contract-modification-for-wroub30jyzj7.html
[2] https://www.marketscreener.com/news/emergent-biosolutions-awarded-30-million-contract-modification-for-cyfendus-anthrax-vaccine-adsor-ce7c50d3df8af621